126 related articles for article (PubMed ID: 29407773)
1. Preclinical evaluation of the mono-PEGylated recombinant human interleukin-11 in cynomolgus monkeys.
Yu KM; Lau JY; Fok M; Yeung YK; Fok SP; Zhang S; Ye P; Zhang K; Li X; Li J; Xu Q; Wong WT; Choo QL
Toxicol Appl Pharmacol; 2018 Mar; 342():39-49. PubMed ID: 29407773
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and toxicokinetics assessment of the mono-PEGylated recombinant human interleukin-11 in cynomolgus monkeys.
Li X; Pang PS; Zhang S; Ru L; Yuan Z; Liu R; Choo QL; Wang Q; Song J; Xu Q; Zhang K; Yu KM; Xu Z
Life Sci; 2020 Oct; 259():118244. PubMed ID: 32791145
[TBL] [Abstract][Full Text] [Related]
3. A 9-Month Toxicity and Toxicokinetic Assessment of Subcutaneous Pegylated Human C-peptide (CBX129801) in Cynomolgus Monkeys.
Naas D; Morris T; Kousba A; Mazzoni M
Int J Toxicol; 2015; 34(4):318-24. PubMed ID: 26111539
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of subcutaneous injection and intravenous infusion of recombinant human interleukin-12 and recombinant human interleukin-12 combined with hepatitis B surface antigen in cynomolgus monkeys.
Li R; Deng F; Fu Y; Zhang Y; Wan H; Zhou D; Gu J; Xu J
Pharmacology; 2010; 85(6):319-27. PubMed ID: 20516733
[TBL] [Abstract][Full Text] [Related]
5. Adverse vacuolation in multiple tissues in cynomolgus monkeys following repeat-dose administration of a PEGylated protein.
Fletcher AM; Tellier P; Douville J; Mansell P; Graziano MJ; Mangipudy RS; Brodie TA; Achanzar WE
Toxicol Lett; 2019 Dec; 317():120-129. PubMed ID: 31580884
[TBL] [Abstract][Full Text] [Related]
6. Subchronic safety evaluation of EPO-018B, a pegylated peptidic erythropoiesis stimulating agent, after 5-week subcutaneous injection in Cynomolgus monkeys and Sprague-Dawley rats.
Gong XL; Zhang XD; Li J; Zhang XF; Zong Y; Lu GC; Yuan BJ
Food Chem Toxicol; 2013 Oct; 60():252-62. PubMed ID: 23911802
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and Pharmacodynamic Evaluation of Different PEGylated Human Interleukin-11 Preparations in Animal Models.
Yu KM; Yiu-Nam Lau J; Fok M; Yeung YK; Fok SP; Hu TL; Tsai YJ; Choo QL
J Pharm Sci; 2018 Nov; 107(11):2755-2763. PubMed ID: 30005986
[TBL] [Abstract][Full Text] [Related]
8. Pegbelfermin, a PEGylated FGF21 analogue, has pharmacology without bone toxicity after 1-year dosing in skeletally-mature monkeys.
Thompson KE; Guillot M; Graziano MJ; Mangipudy RS; Chadwick KD
Toxicol Appl Pharmacol; 2021 Oct; 428():115673. PubMed ID: 34364948
[TBL] [Abstract][Full Text] [Related]
9. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.
Leonard JP; Sherman ML; Fisher GL; Buchanan LJ; Larsen G; Atkins MB; Sosman JA; Dutcher JP; Vogelzang NJ; Ryan JL
Blood; 1997 Oct; 90(7):2541-8. PubMed ID: 9326219
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Ginsberg M; Rittweger K; Vuky J; Yu R; Fettner S; Hooftman L
J Clin Oncol; 2001 Mar; 19(5):1312-9. PubMed ID: 11230473
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and hematological effects of the PEGylated thrombopoietin peptide mimetic GW395058 in rats and monkeys after intravenous or subcutaneous administration.
de Serres M; Yeager RL; Dillberger JE; Lalonde G; Gardner GH; Rubens CA; Simkins AH; Sailstad JM; McNulty MJ; Woolley JL
Stem Cells; 1999; 17(6):316-26. PubMed ID: 10606160
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects of interferon alpha-2b and pegylated interferon alpha-2b on menstrual cycles and ovarian hormones in cynomolgus monkeys.
Enright BP; Compton DR; Collins N; Davis T; McIntyre BS
Birth Defects Res B Dev Reprod Toxicol; 2009 Feb; 86(1):29-39. PubMed ID: 19243028
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
14. Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis.
Moreland L; Gugliotti R; King K; Chase W; Weisman M; Greco T; Fife R; Korn J; Simms R; Tesser J; Hillson J; Caldwell J; Schnitzer T; Lyons D; Schwertschlag U
Arthritis Res; 2001; 3(4):247-52. PubMed ID: 11438043
[TBL] [Abstract][Full Text] [Related]
15. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates.
Yang Z; Wang J; Lu Q; Xu J; Kobayashi Y; Takakura T; Takimoto A; Yoshioka T; Lian C; Chen C; Zhang D; Zhang Y; Li S; Sun X; Tan Y; Yagi S; Frenkel EP; Hoffman RM
Cancer Res; 2004 Sep; 64(18):6673-8. PubMed ID: 15374983
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys and comparative pharmacokinetics in humans.
Sung C; Parry TJ; Riccobene TA; Mahoney A; Roschke V; Murray J; Gu ML; Glenn JK; Caputo F; Farman C; Odenheimer DJ
AAPS PharmSci; 2002; 4(2):E8. PubMed ID: 12102617
[TBL] [Abstract][Full Text] [Related]
17. Chronic preclinical safety evaluation of EPO-018B, a pegylated peptidic erythropoiesis-stimulating agent in monkeys and rats.
Gong XL; Gu XL; Chen YC; Zhu H; Xia ZN; Li JZ; Lu GC
Toxicol Appl Pharmacol; 2016 Sep; 307():45-61. PubMed ID: 27457977
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human interleukin-3 induces extramedullary hematopoiesis at subcutaneous injection sites in cynomolgus monkeys.
Khan KN; Kats AA; Fouant MM; Snook SS; Mckearn JP; Alden CL; Smith PF
Toxicol Pathol; 1996; 24(4):391-7. PubMed ID: 8864180
[TBL] [Abstract][Full Text] [Related]
19. Extended activity in cynomolgus monkeys of a granulocyte colony-stimulating factor mutein conjugated with high molecular weight polyethylene glycol.
Eliason JF; Greway A; Tare N; Inoue T; Bowen S; Dar M; Yamasaki M; Okabe M; Horii I
Stem Cells; 2000; 18(1):40-5. PubMed ID: 10661570
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetics of PEG recombinant human interleukin-6 in rats].
He XL; Yang G; Yin HL; Zhang XM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 40(1):149-52. PubMed ID: 19292067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
